- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.11.25 | FDA's revolving door reveals Pazdur as new CDER head | ||
| 12.11.25 | Dyno Therapeutics and Trisk Bio partner for strategic manufacture | ||
| 12.11.25 | March Bio's MB-105 gains FDA RMAT for CD5+ T-cell lymphoma | ||
| 11.11.25 | FDA calls for black box warning to be removed from HRT products | ||
| 11.11.25 | Lyell acquires worldwide rights from ICT to CAR T-cell therapy | ||
| 11.11.25 | Novartis opens California site for RLT manufacturing | ||
| 10.11.25 | Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal | ||
| 10.11.25 | CPHI 2025: directing AI-driven innovation to harness Europe's data edge | ||
| 10.11.25 | Harbour BioMed and Evinova collaborate on AI biologics | ||
| 10.11.25 | Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats | ||
| 10.11.25 | Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer | ||
| 10.11.25 | SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases | ||
| 07.11.25 | Rhythm forced to wait for Imcivree expansion as FDA delays decision | ||
| 07.11.25 | J&J's Darzalex gains first FDA approval in smouldering multiple myeloma | ||
| 07.11.25 | Trump hits long-term pledge as US prices of weight loss drugs slashed | ||
| 07.11.25 | Abzena and Mabqi partner for drug development solution | ||
| 07.11.25 | Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz | ||
| 06.11.25 | J&J's Caplyta wins MDD approval to extend revenue horizon | ||
| 06.11.25 | Former blockbuster Linzess grows label with paediatric IBS-C approval | ||
| 06.11.25 | Novo Nordisk's oral Wegovy reduces cardiovascular risk factors in obesity | ||
| 06.11.25 | Cencora to invest $1bn in US pharma distribution network | ||
| 06.11.25 | Leukogene Therapeutics gains FDA ODD status for M2T-CD33 | ||
| 05.11.25 | Novo Nordisk latest outlook trim shows "quick momentum loss" | ||
| 05.11.25 | Agentic, deeply embedded AI constitutes the "next wave" of tech | ||
| 05.11.25 | Avant and SGAustria form JV to develop diabetes therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .